4.2 Dosage Form Formulation & Excipients

4.2 Dosage Form Formulation & Excipients

Core Concept: A finished pharmaceutical dosage form is a complex drug delivery system comprising active pharmaceutical ingredients (APIs) and non-therapeutic inert substances known as excipients. Formulation design transforms raw drug molecules into stable, effective, reproducible, and patient-compliant dosage forms.

---

1. Solid Dosage Forms: Tablets, Capsules, and Modified-Release Systems

Solid dosage forms account for over $70%$ of all administered pharmaceuticals due to their dosing accuracy, stability, ease of self-administration, and cost-effective manufacturing.

Tablet Manufacturing Technologies

Tablets are solid unit dosage forms prepared by compressing uniform volumes of particle formulations inside a die cavity using upper and lower punches.

• Direct Compression: Blending API directly with compressible excipients (e.g., microcrystalline cellulose, spray-dried lactose) followed by compression. Ideal for moisture- and heat-sensitive APIs but requires excellent powder flowability and compressibility.
• Wet Granulation: Liquid binder is added to powder mixtures to form wet granules, which are dried, milled, and compressed. Improves content uniformity and flow for low-dose or poorly flowable drugs.
• Dry Granulation (Roller Compaction/Slugging): Powder blend is compacted under high mechanical pressure into ribbons or slugs, then milled into granules. Used for moisture-sensitive APIs with poor flow.

Modified-Release Oral Dosage Forms

Conventional immediate-release (IR) formulations release API rapidly upon administration. Modified-release (MR) formulations alter release location or rate:

1. Extended-Release (ER/CR/SR): Maintains therapeutic drug concentrations in blood over prolonged intervals (e.g., $12-24 \text{ hours}$). Mechanisms include:
   • Hydrophilic Matrix Systems: Polymeric networks (e.g., HPMC) hydrate upon contact with water, forming a viscous gel layer through which drug diffuses.
   • Osmotic-Controlled Release (OROS): Rigid semipermeable membrane encloses an osmotic core with a laser-drilled orifice. Water influx creates hydrostatic pressure, pumping drug out at a precise zero-order rate independent of GI $p H$ or motility.
2. Delayed-Release (Enteric Coated): Protects stomach mucosa from irritating drugs or protects acid-labile drugs (e.g., omeprazole) from gastric degradation. Utilizes $p H$-sensitive polymers (e.g., cellulose acetate phthalate, Eudragit L/S) that remain insoluble in acidic gastric juice ($p H < 3$) but dissolve rapidly in duodenal fluid ($p H > 5.5$).

---

2. Liquid Dosage Forms, Disperse Systems, and Surfactant Physics

Liquid dosage forms comprise monophasic solutions and polyphasic disperse systems (suspensions and emulsions).

Suspensions and Stokes' Law

Suspensions are coarse dispersions of insoluble solid API particles ($> 0.5 \ \mu\text{m}$) suspended in a liquid medium. Physical stability requires minimizing particle sedimentation velocity ($v$), defined by Stokes' Law:

$v = \frac{d^2 \cdot (\rho_p - \rho_f) \cdot g}{18 \cdot \eta}$

Formulations are structured as flocculated systems, where weak van der Waals attraction forms loose particle aggregates (flocs). Although flocs sediment rapidly, they form a porous volume that is easily resuspended upon shaking, preventing dense, irreversible caking.

Emulsions and Surfactant HLB Values

Emulsions are thermodynamically unstable systems consisting of two immiscible liquid phases stabilized by an emulsifying agent (surfactant).

Surfactants reduce interfacial tension by orienting their hydrophilic heads and lipophilic tails across phase boundaries. Surfactants are classified using the Hydrophilic-Lipophilic Balance (HLB) scale (Griffin scale, range $1-20$):

$\text{HLB} = 20 \times \frac{M_h}{M}$

where $M_h$ is the molecular mass of the hydrophilic portion and $M$ is total molecular mass.

HLB Value:  1 ----- 3 ----------- 6 ----- 8 --------------- 16 ----- 18 - 20
Function:   [ antifoam ] [ W/O emulsifiers ] [ wetting ] [ O/W emulsifiers ] [ solubilizers ]

---

3. Parenteral Formulations: Sterility, Isotonicity, and Pyrogen Control

Parenteral dosage forms (intravenous, intramuscular, subcutaneous) bypass the body's protective epithelial barriers, demanding absolute quality control standards.

Sterility and Endotoxin Limits

• Sterility: Absolute absence of viable microorganisms, verified by Sterility Testing (USP $<71>$).
• Bacterial Endotoxins (Pyrogens): Toxic lipopolysaccharides (LPS) derived from Gram-negative bacterial outer membranes. Pyrogens cause severe febrile responses and septic shock upon injection. Endotoxin limits are quantified using the Limulus Amebocyte Lysate (LAL) assay (USP $<85>$), which uses horseshoe crab blood lysate to form gel clots in the presence of endotoxins.
• Depyrogenation: Endotoxins are heat-stable and resist autoclaving; depyrogenation requires dry heat incineration at $\ge 250^\circ\text{C}$ for at least 30 minutes.

Isotonicity Calculations

Parenteral solutions must be isotonic with human blood plasma (approx. $290 \text{ mOsmol/kg}$ or $\Delta T_f = 0.52^\circ\text{C}$) to prevent red blood cell hemolysis (hypertonic shrinkage or hypotonic lysis).

Isotonicity adjustment using the Sodium Chloride Equivalent ($E$-value) method:

$E = 17 \times \frac{L_{\text{iso}}}{MW}$

where $E$ represents the grams of $NaCl$ equivalent to $1 \text{ g}$ of drug. The required $NaCl$ addition per $100 \text{ mL}$ is:

$\text{Grams } NaCl \text{ Needed} = 0.90\% - \sum (C_{\text{drug}} \times E)$

---

4. Excipient Functions and Incompatibilities

Excipients perform specific functional roles but can undergo detrimental chemical or physical interactions with APIs:

Critical Incompatibility Mechanisms

1. Maillard Reaction: Reducing sugars (such as lactose or dextrose) undergo nucleophilic addition with drugs containing primary or secondary amine groups (e.g., fluoxetine, hydrochlorothiazide), leading to brown discoloration and active potency loss.
2. Magnesium Stearate Hydrophobic Waterproofing: Prolonged blending of magnesium stearate coats drug particles in a hydrophobic film, dramatically slowing tablet wetting and drug dissolution rate.